Search results
Aimin Xu is currently a Chair Professor jointly appointed by the Department of Medicine and the Department of Pharmacology & Pharmacy, and also the director for State Key Laboratory of Pharmaceutical Biotechnology (www.sklpb.hku.hk) at the University of Hong Kong.
Professor Aimin Xu is currently a Professor in the Department of Medicine, School of Clinical Medicine and also the director for State Key Laboratory of Pharmaceutical Biotechnology (www.sklpb.hku.hk) at the University of Hong Kong.
Our primary research interest is to investigate the role of adipokines in the pathogenesis of obesity-related insulin resistance, systemic inflammation, T2DM and vascular dysfunctions in animal models and human subjects.
Professor Aimin Xu and his research associates Research Interests Obesity is a major risk factor of type 2 diabetes (T2DM), insulin resistance and cardiovascular diseases (CVDs).
Aimin Xu. Department of Medicine, Department of Pharmacology and Pharmacy, the University of Hong Kong. Verified email at hku.hk. Obesity diabetes biomarker discovery adipocyte biology adipokines. Articles Cited by Public access. Title. ... Y Wang, A Xu, C Knight, LY Xu, GJS Cooper. Journal of Biological Chemistry 277 (22), 19521-19529, 2002 ...
My major research interest is on discovery and functional characterization of novel adipokines and hepatokines involved in the pathogenesis of obesity-related cardio-metabolic complications.
Aimin XU | Cited by 33,716 | of The University of Hong Kong, Hong Kong (HKU) | Read 680 publications | Contact Aimin XU
